REESE DAVID M 4
4 · AMGEN INC · Filed Feb 21, 2025
Insider Transaction Report
Form 4
AMGEN INCAMGN
REESE DAVID M
EVP & Chief Technology Officer
Transactions
- Sale
Common Stock
2025-02-19$293.22/sh−8,711$2,554,224→ 62,147 total - Exercise/Conversion
Nqso (Right to Buy)
2025-02-19−8,711→ 0 totalExercise: $156.35From: 2018-05-03Exp: 2026-05-03→ Common Stock (8,711 underlying) - Sale
Common Stock
2025-02-21$304.44/sh−25,225$7,679,524→ 36,922 total - Exercise/Conversion
Common Stock
2025-02-19$156.35/sh+8,711$1,361,965→ 70,858 total
Footnotes (4)
- [F1]These shares were acquired in connection with the exercise of stock options expiring on May 3, 2026.
- [F2]The price reported is an average price. The prices ranged from $291.90 to $295.97 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- [F3]The price reported is an average price. The prices ranged from $297.19 to $305.33 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.
- [F4]These shares include 707 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.